Optimizing Pediatric HIV-1 Treatment in Infants With Prophylactic Exposure to Nevirapine, Nairobi, Kenya

Phase 3

Terminated

• Conditions: HIV Infections
• Interventions: Drug: AZT/3TC/NVP (zidovudine/lamivudine/nevirapine); Drug: AZT/3TC/ABC (zidovudine/lamivudine/abacavir); Drug: d4T/3TC/NVP (stavudine/lamivudine/nevirapine); Drug: d4T/3TC/ABC (stavudine/lamivudine/abacavir); Drug: ddI/ABC/LPV/r (didanosine/abacavir/lopinavir-ritonavir); Drug: ABC/3TC/NVP (abacavir/lamivudine/nevirapine); Drug: ABC/ ddI or TDF / NVP or EFV (abacavir / didanosine or tenofovir / nevirapine or efavirenz)

• Registration Number: NCT00427297
• Lead Sponsor: University of Washington

Brief Summary

Globally, children who acquire HIV-1 increasingly do so in the context of maternal antiretroviral prophylaxis. It is important to determine whether maternal antiretroviral prophylaxis should alter infant treatment regimens. Nevirapine (NVP) is commonly used for PMTCT and is also a commonly used first-line drug for treatment of pediatric HIV-1. Approximately half of infants exposed to NVP have detectable NVP resistance early in infancy, with loss of detectable resistance over time. Thus, if an HIV-1 infected child was exposed to single-dose NVP prophylaxis, the question remains whether NVP or any NNRTI can be used effectively in therapeutic regimens. Alternative PI-based regimens are associated with heat-lability, poor palatability, cumulative toxicity, and fewer salvage options. This poses challenges for pediatric PI-based highly active antiretroviral therapy (HAART) in settings without refrigeration and limited antiretroviral repertoire. It is plausible that in older NVP-exposed infants (older than 6 months since exposure) who are genotypically NVP-susceptible, that nevirapine will be effective and useful.

We propose to study resistance in a pediatric HIV-1 clinical trial involving 100 children. Among children enrolled at between 6 and 18 months of age, we will provide real-time field-based genotypic NVP-resistance testing, and randomize 100 NVP-susceptible children to NVP-containing versus NVP-sparing HAART to compare therapeutic response, adverse events, and morbidity in the 2 arms during 2-year follow-up. Follow-up in these studies will be closely monitored by an external Data Safety and Monitoring Board (DSMB).

Detailed Description

Hypotheses

1. Infants older than 6 months who do not have detectable nevirapine resistance on genotypic testing will respond equivalently to a nevirapine-sparing or a nevirapine-containing HAART regimen, despite previous single-dose nevirapine exposure.

2. Genotypic drug resistance levels may predict response to therapy and clinical progression.

Specific Aims/Primary Objectives

1. To compare response to therapy (viral levels, CD4%, growth, and morbidity) in infants without detectable nevirapine-resistance on population-based sequencing who are randomized to nevirapine-containing versus nevirapine-sparing HAART.

2. To develop methods to detect and quantify nevirapine resistance mutations present at low frequency in the virus population in order to examine the relationship between the copy number of such variants and virologic failure of infants treated with nevirapine-containing HAART.

Secondary Aim/Secondary Objective: To determine predictors of non-progression in these studies, including: age, time since nevirapine-exposure, adherence, HIV-1 specific immune responses, baseline HIV-1 RNA, CD4 percent, and immune activation.

Design: Randomized clinical trial in which infant 6-18 months of age will be randomized to nevirapine containing versus nevirapine sparing HAART regimen and followed for 24 months.

Population: HIV-1 infected infants (6-12 months) meeting eligibility will be enrolled. Infants who were exposed to nevirapine in-utero or following delivery, with no detectable resistance to nevirapine will be eligible for enrollment.

Sample size: 100 infants will be enrolled (50 infants in each arm).

Treatment: All infants will be treated with NVP containing or sparing HAART. The regimen will be prescribed according to WHO and Kenyan national guidelines on dosage and combination of antiretroviral drugs. The HAART regimen that will be used in this study are:

First line regimen:

For infants on NVP containing HAART

* AZT/3TC/NVP (zidovudine/lamivudine/nevirapine)

* d4T/3TC/NVP (stavudine/lamivudine/nevirapine)

* ABC/3TC/NVP (abacavir/lamivudine/nevirapine)

For infants on NVP sparing HAART

* AZT/3TC/ABC (zidovudine/lamivudine/abacavir)

* d4T/3TC/ABC (stavudine/lamivudine/abacavir)

For children who have anaemia (Hb of \<8g/dl), AZT will be substituted for d4T.

Second line regimen:

* ddI/ABC/LPV/r (didanosine/abacavir/lopinavir-ritonavir (kaletra))

* ABC / ddI or TDF / NVP or EFV (abacavir / didanosine or tenofovir / nevirapine or efavirenz) Among children randomized to NVP sparing HAART, who will be initiated on a regimen containing lopinavir/ritonavir, zidovudine and lamivudine will be substituted with abacavir and didanosine or tenofovir (TDF) and lopinavir/ ritonavir will be replaced with nevirapine or efavirenz (EFV) in case of treatment failure of the LPV/r containing regimen.

Study Timeline

• Study First Submitted: 2007-01-22
• Study First Submitted QC: 2007-01-26
• Study First Posted: 2007-01-29
• Study Start: 2007-09
• Primary Completion: 2009-05
• Study Completion: 2009-12
• Results First Submitted: 2018-06-29
• Status Verified: 2018-07
• Results First Submitted QC: 2018-07-27
• Last Update Submitted: 2018-07-27
• Results First Posted: 2018-08-27
• Last Update Posted: 2018-08-27

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 34

Inclusion Criteria

• 6-18 months age
• HIV-1 DNA detection with confirmation (positive on two HIV-1 DNA filter paper tests)
• Mother exposed to NVP-containing PMTCT regimen during currently ended pregnancy and/or infant received NVP-containing PMTCT regimen
• Infant susceptible to NVP (i.e. no detectable NVP resistance on genotypic testing)
• Caregiver of infant plans to reside in Nairobi for at least 3 years
• Caregiver is able to provide sufficient location information

Read More

Exclusion Criteria

• Infant has received any prior antiretroviral therapy (expect prophylaxis for PMTCT)
• Infant has evidence of active tuberculosis
• Mother currently receiving NVP-containing HAART and breastfeeding the infant

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
NVP-sparing	ddI/ABC/LPV/r (didanosine/abacavir/lopinavir-ritonavir)	Infants randomized to this arm will receive nevirapine-sparing HAART
NVP-containing	ABC/3TC/NVP (abacavir/lamivudine/nevirapine)	Infants randomized to this arm will receive nevirapine-containing HAART regimen
NVP-containing	d4T/3TC/NVP (stavudine/lamivudine/nevirapine)	Infants randomized to this arm will receive nevirapine-containing HAART regimen
NVP-containing	AZT/3TC/NVP (zidovudine/lamivudine/nevirapine)	Infants randomized to this arm will receive nevirapine-containing HAART regimen
NVP-sparing	AZT/3TC/ABC (zidovudine/lamivudine/abacavir)	Infants randomized to this arm will receive nevirapine-sparing HAART
NVP-sparing	d4T/3TC/ABC (stavudine/lamivudine/abacavir)	Infants randomized to this arm will receive nevirapine-sparing HAART
NVP-sparing	ABC/ ddI or TDF / NVP or EFV (abacavir / didanosine or tenofovir / nevirapine or efavirenz)	Infants randomized to this arm will receive nevirapine-sparing HAART

Primary Outcome Measures

Name	Time	Method
Incidence of Mortality	2 years	Death during follow-up
Immunologic Failure	2 years	Immunologic treatment failure was defined as CD4% dropping below 15%, after a previous result greater than or equal to 15% (following along WHO Guidelines).
Viral Failure	2 years	Virologic treatment failure was defined as follow-up (at least 24 weeks after enrollment date) viral load \> 400 copies.

Secondary Outcome Measures

Name	Time	Method
Incidence of Severe Adverse Events (Excluding Mortality)	2 years

Trial Locations

Locations (1)

Kenyatta National Hospital, University of Nairobi; 🇰🇪 Nairobi, Kenya